Losartan review grows for fourth time, focusing on dozens more items
A review for medication used to treat hypertension has extended for a fourth time, focusing on more variations of generic losartan delivered by Torrent Pharmaceuticals.
A review of Torrent losartan items was initially issued in December. A Thursday update posted by the Food and Drug Administration extended it to incorporate dozens more.
Other review developments were reported in January and March.
The review has focused on losartan potassium tablets and losartan potassium/hydrochlorothiazide tablets. The pills have been flagged for containing an impurity known as NMBA.
“Torrent is only recalling lots of losartan-containing products that contain NMBA above the acceptable daily intake levels released by the FDA,” the agency says.
As per the FDA, losartan is utilized to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for treating nephropathy in Type 2 diabetics.
The FDA prompts patients on these meds to keep taking them until they can find an option.
“Risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment,” the FDA says.